Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: a Randomized Phase II Study

PURPOSE: Increased growth factor signaling may contribute to tamoxifen resistance. This randomized Phase II trial assessed tamoxifen plus placebo or the EGFR inhibitor gefitinib in ER-positive metastatic breast cancer. EXPERIMENTAL DESIGN: Patients with newly metastatic disease or recurring after ad...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Osborne, C. Kent, Neven, Patrick, Dirix, Luc Y., Mackey, John R., Robert, Jean, Underhill, Craig, Schiff, Rachel, Gutierrez, Carolina, Migliaccio, Ilenia, Anagnostou, Valsamo K., Rimm, David L., Magill, Patrick, Sellers, Mark
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3074404/
https://ncbi.nlm.nih.gov/pubmed/21220480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-1869
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados